Tolmetin

• Anti-Inflammatory Agents, Non-Steroidal
• Cyclooxygenase Inhibitors
• ATC:M01AB03
• ATC:M02AA21

• Acide tiludronique [INN-French]
• Acido tiludronico [INN-Spanish]
• Acidum tiludronicum
• Acidum tiludronicum [INN-Latin]
• Skelid
• Tiludronate disodium
• Tiludronic Acid Disodium Salt
• Tiludronic acid
• Tiludronic acid [BAN:INN]

• No information avaliable

C₁₅H₁₅NO₃

http://www.rxlist.com/cgi/generic2/tolmetin.htm

Tolmetin MSDS

No information avaliable

257.285 g/mol

156 ^oC

222 mg/L

Solid

2.469

Tablet (oral, equivalent to 200 mg or 600 mg of tolmetin); Capsule (oral, equivalent to 400 mg of tolmetin)

For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.

Tolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.

Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.

Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.

Humans and other mammals